Arcutis Biotherapeutics (ARQT) Cash & Equivalents (2019 - 2026)

Arcutis Biotherapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $308000.0 for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 50.08% year-over-year to $308000.0; the TTM figure through Mar 2026 stood at $308000.0 (down 50.08% YoY), while the FY2025 annual figure was $42.9 million, down 39.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $308000.0, down from $42.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $134.9 million in Q3 2024, with the low at $300000.0 in Q2 2025.
• The 5-year median for Cash & Equivalents is $925000.0 (2023), against an average of $21.6 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 98.54% in 2023, then soared 14883.44% in 2024.
• Arcutis Biotherapeutics' Cash & Equivalents stood at $1.2 million in 2022, then decreased by 25.04% to $925000.0 in 2023, then surged by 7611.89% to $71.3 million in 2024, then slumped by 39.85% to $42.9 million in 2025, then sank by 99.28% to $308000.0 in 2026.
• Business Quant data shows ARQT's Cash & Equivalents at $308000.0 in Q1 2026, $42.9 million in Q4 2025, and $47.1 million in Q3 2025.